AdvisorShares Investments LLC Grows Stock Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

AdvisorShares Investments LLC raised its holdings in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 47.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 99,810 shares of the company’s stock after purchasing an additional 32,030 shares during the quarter. AdvisorShares Investments LLC owned 0.36% of Vistagen Therapeutics worth $294,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Virtu Financial LLC lifted its holdings in shares of Vistagen Therapeutics by 30.5% in the 3rd quarter. Virtu Financial LLC now owns 20,210 shares of the company’s stock valued at $61,000 after acquiring an additional 4,722 shares during the last quarter. R Squared Ltd purchased a new stake in Vistagen Therapeutics during the fourth quarter valued at approximately $25,000. Blair William & Co. IL lifted its stake in shares of Vistagen Therapeutics by 11.3% in the 4th quarter. Blair William & Co. IL now owns 98,466 shares of the company’s stock valued at $290,000 after purchasing an additional 10,000 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Vistagen Therapeutics in the 3rd quarter valued at approximately $59,000. Finally, Boothbay Fund Management LLC purchased a new position in shares of Vistagen Therapeutics in the 4th quarter worth approximately $66,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

Vistagen Therapeutics Stock Performance

NASDAQ:VTGN opened at $2.29 on Wednesday. The firm has a market capitalization of $66.09 million, a PE ratio of -1.55 and a beta of 0.56. The stock’s fifty day moving average is $2.46 and its 200 day moving average is $2.71. Vistagen Therapeutics, Inc. has a fifty-two week low of $1.90 and a fifty-two week high of $4.96.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Thursday, February 13th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.02. Vistagen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 48.12%. The business had revenue of $230 billion for the quarter, compared to the consensus estimate of $0.18 million. Equities analysts forecast that Vistagen Therapeutics, Inc. will post -1.77 EPS for the current year.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.